Close Menu
Best in TechnologyBest in Technology
  • News
  • Phones
  • Laptops
  • Gadgets
  • Gaming
  • AI
  • Tips
  • More
    • Web Stories
    • Global
    • Press Release

Subscribe to Updates

Get the latest tech news and updates directly to your inbox.

What's On

Infinix GT 30 5G+ Confirmed to Launch in India Soon; Cyber Mecha Design 2.0 Teased

1 August 2025

Measles Cases Are Soaring in Mexico

1 August 2025

Review: Asus Chromebook CX14

1 August 2025
Facebook X (Twitter) Instagram
Just In
  • Infinix GT 30 5G+ Confirmed to Launch in India Soon; Cyber Mecha Design 2.0 Teased
  • Measles Cases Are Soaring in Mexico
  • Review: Asus Chromebook CX14
  • A New Katamari Game, Octopath Traveler 0, and More Are Coming to Switch 2
  • Inside the Summit Where China Pitched Its AI Agenda to the World
  • States Are Moving to Protect Access to Vaccines
  • Still Using Windows 10? Here’s How to Get Another Year of Updates for Free
  • Oppo K13 Turbo, K13 Turbo Pro India Launch Timeline Leaked
Facebook X (Twitter) Instagram Pinterest Vimeo
Best in TechnologyBest in Technology
  • News
  • Phones
  • Laptops
  • Gadgets
  • Gaming
  • AI
  • Tips
  • More
    • Web Stories
    • Global
    • Press Release
Subscribe
Best in TechnologyBest in Technology
Home » The FDA Just Approved a Long-Lasting Injection to Prevent HIV
News

The FDA Just Approved a Long-Lasting Injection to Prevent HIV

News RoomBy News Room20 June 20253 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
Share
Facebook Twitter LinkedIn Pinterest Email

The US Food and Drug Administration has just approved lenacapavir, an injectable form of HIV prevention that is almost 100 percent effective and requires only two doses per year. Science magazine described the medicine the most important scientific advance of 2024.

In clinical trials, lenacapavir proved to be 99.9 percent effective in preventing HIV infection through sexual transmission in people weighing more than 35 kilograms. The drug, an antiretroviral, works not by stimulating an immune response, but by blocking HIV from reproducing during its early stages—specifically, by disrupting the function of the virus’s capsid protein. This happens so long as the body receives injections every six months.

Lenacapavir has already been approved in some countries as a treatment for HIV in people with forms of the virus that are resistant to other treatments. However, prior to this week, its prophylactic use had not been approved anywhere, making the FDA’s decision a significant new development in the fight against the HIV/AIDS epidemic.

The drug is not the first medicine that can be taken preemptively to protect against an HIV infection: pre-exposure prophylaxis (PrEP) pills were already available in many countries, including the United States. But these must be taken every day, and ensuring ongoing access to these medicines, and that people actually remember to take them, is a known challenge. It’s hoped the long-lasting effects of lenacapavir will make it easier for people to stay protected against the virus.

According to its creator, Gilead Sciences, lenacapavir will be marketed under the trade name Yeztugo. The company has committed to manufacturing 10 million doses by 2026.

“This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,” Daniel O’Day, president and CEO of Gilead, said in a statement on Wednesday.

However, lenacapavir’s price may be a barrier to access. Yeztugo will have an annual list price of $28,218 per person in the US. Winnie Byanyima, executive director of of the Joint United Nations Program on HIV/AIDS (UNAIDS), has also flagged in the past that the drug is unaffordable for many people in Africa, where the medicine has the potential to have the biggest impact. Roughly two-thirds of the people living with HIV worldwide live in sub-Saharan Africa.

Gilead said in a statement last year that it had been “developing a strategy to enable broad, sustainable access globally” to lenacapavir, although the company has not yet provided detailed information on how it will do this. One option could be “voluntary licensing,” where other companies are granted permission to produce and sell generic versions of a patented product exclusively to people in certain (often low-income) countries. Researchers at the University of Liverpool in the UK have calculated that a year’s worth of lenacapavir could be made available for as little as $25.

This story originally appeared on WIRED en Español and has been translated from Spanish.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleiPhone 16 Pro, iPhone 16 Pro Max Available at Discounted Prices on Flipkart: See Offers
Next Article Oppo Reno 14 5G Series Global Launch Date Announced; Amazon, Flipkart Tease Online Availability in India

Related Articles

News

Measles Cases Are Soaring in Mexico

1 August 2025
News

Review: Asus Chromebook CX14

1 August 2025
News

A New Katamari Game, Octopath Traveler 0, and More Are Coming to Switch 2

31 July 2025
News

Inside the Summit Where China Pitched Its AI Agenda to the World

31 July 2025
News

States Are Moving to Protect Access to Vaccines

31 July 2025
News

Still Using Windows 10? Here’s How to Get Another Year of Updates for Free

31 July 2025
Demo
Top Articles

ChatGPT o1 vs. o1-mini vs. 4o: Which should you use?

15 December 2024103 Views

Costco partners with Electric Era to bring back EV charging in the U.S.

28 October 202495 Views

Oppo Reno 14, Reno 14 Pro India Launch Timeline and Colourways Leaked

27 May 202582 Views

Subscribe to Updates

Get the latest tech news and updates directly to your inbox.

Latest News
News

States Are Moving to Protect Access to Vaccines

News Room31 July 2025
News

Still Using Windows 10? Here’s How to Get Another Year of Updates for Free

News Room31 July 2025
Phones

Oppo K13 Turbo, K13 Turbo Pro India Launch Timeline Leaked

News Room31 July 2025
Most Popular

The Spectacular Burnout of a Solar Panel Salesman

13 January 2025125 Views

ChatGPT o1 vs. o1-mini vs. 4o: Which should you use?

15 December 2024103 Views

Costco partners with Electric Era to bring back EV charging in the U.S.

28 October 202495 Views
Our Picks

A New Katamari Game, Octopath Traveler 0, and More Are Coming to Switch 2

31 July 2025

Inside the Summit Where China Pitched Its AI Agenda to the World

31 July 2025

States Are Moving to Protect Access to Vaccines

31 July 2025

Subscribe to Updates

Get the latest tech news and updates directly to your inbox.

Facebook X (Twitter) Instagram Pinterest
  • Privacy Policy
  • Terms of use
  • Advertise
  • Contact Us
© 2025 Best in Technology. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.